Back to Search
DANIELA MATEI, M.D.
M.D.
Hematology & Oncology Physician
NPI: 1558327486IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
01056559(IN)
CMS Specialties
PrimaryHEMATOLOGY/ONCOLOGY
Education
OTHER
Class of 1992
Research & Publications (20)
Chronic physical effects and health care utilization in long-term ovarian germ cell tumor survivors: a Gynecologic Oncology Group study.
PMID 19636015·J Clin Oncol·2009
4-observational
Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.
PMID 19577796·Gynecol Oncol·2009
3-trial
Intraoperative radiotherapy during radical prostatectomy for intermediate-risk to locally advanced prostate cancer: treatment technique and evaluation of perioperative and functional outcome vs standard radical prostatectomy, in a matched-pair analysis.
PMID 19624597·BJU Int·2009
4-observational
Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.
PMID 19515553·Eur J Cancer·2009
3-trial
Robotic vs open prostatectomy in a laparoscopically naive centre: a matched-pair analysis.
PMID 19426191·BJU Int·2009
4-observational
Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity.
PMID 19324884·J Biol Chem·2009
8-other
Biostatistical study of suicide features in Mures County (Romania).
PMID 19282229·Leg Med (Tokyo)·2009
8-other
Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer.
PMID 19139180·Ann Oncol·2009
3-trial
A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.
PMID 18692224·Gynecol Oncol·2008
3-trial
Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling.
PMID 18667446·Carcinogenesis·2008
8-other
Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
PMID 18618737·Cancer·2008
3-trial
Identification and characterization of ovarian cancer-initiating cells from primary human tumors.
PMID 18519691·Cancer Res·2008
8-other
Transabdominal ultrasonography, computed tomography and electronic portal imaging for 3-dimensional conformal radiotherapy for prostate cancer.
PMID 17960336·Strahlenther Onkol·2007
4-observational
Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase.
PMID 17671187·Cancer Res·2007
7-preclinical
The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells.
PMID 17079230·J Biol Chem·2007
7-preclinical
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
PMID 16896006·J Clin Oncol·2006
3-trial
Sensitivity and detection rate of a 12-core trans-perineal prostate biopsy: preliminary report.
PMID 16426731·Eur Urol·2006
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 250 E SUPERIOR ST, SUITE 05-2168 GYNECOLOGIC ONCOLOGY
CHICAGO, IL 60611 - Phone
- (312) 695-0990
Quick Facts
- NPI
- 1558327486
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 34
- Publications
- 20
Are you this provider?
Claim Your Profile